Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Memory T-cell enriched haploidentical transplantation with NK cell addback results in promising long-term outcomes: a phase II trial.
Naik S, Li Y, Talleur AC, Selukar S, Ashcraft E, Cheng C, Madden RM, Mamcarz E, Qudeimat A, Sharma A, Srinivasan A, Suliman AY, Epperly R, Obeng EA, Velasquez MP, Langfitt D, Schell S, Métais JY, Arnold PY, Hijano DR, Maron G, Merchant TE, Akel S, Leung W, Gottschalk S, Triplett BM. Naik S, et al. Among authors: qudeimat a. J Hematol Oncol. 2024 Jun 27;17(1):50. doi: 10.1186/s13045-024-01567-0. J Hematol Oncol. 2024. PMID: 38937803 Free PMC article. Clinical Trial.
Intrapulmonary administration of recombinant activated factor VII in pediatric, adolescent, and young adult oncology and hematopoietic cell transplant patients with pulmonary hemorrhage.
Hurley C, McArthur J, Gossett JM, Hall EA, Barker PJ, Hijano DR, Hines MR, Kang G, Rains J, Srinivasan S, Suliman A, Qudeimat A, Ghafoor S. Hurley C, et al. Among authors: qudeimat a. Front Oncol. 2024 Apr 12;14:1375697. doi: 10.3389/fonc.2024.1375697. eCollection 2024. Front Oncol. 2024. PMID: 38680864 Free PMC article.
Disease Status and Interval between Hematopoietic Cell Transplantations Predict Outcome of Pediatric Patients Who Undergo Subsequent Transplantation for Relapsed Hematologic Malignancy.
Epperly R, Li Y, Selukar S, Zeng E, Madden R, Mamcarz E, Naik S, Qudeimat A, Sharma A, Talleur A, Dallas MH, Gottschalk S, Srinivasan A, Triplett B. Epperly R, et al. Among authors: qudeimat a. Transplant Cell Ther. 2024 May;30(5):526.e1-526.e11. doi: 10.1016/j.jtct.2024.02.016. Epub 2024 Feb 20. Transplant Cell Ther. 2024. PMID: 38387720 Free article.
Outcomes following intolerance to calcineurin inhibitor-based graft-versus-host disease prophylaxis in children after allogeneic hematopoietic cell transplantation.
Wu D, Li Y, Bi Y, Lannom TM, Ward DA, Qudeimat A, Madden RM, Sharma A, Epperly R, Mamcarz E, Talleur A, Naik S, Selukar S, Triplett B, Srinivasan A. Wu D, et al. Among authors: qudeimat a. Pediatr Blood Cancer. 2023 Jun 20:e30517. doi: 10.1002/pbc.30517. Online ahead of print. Pediatr Blood Cancer. 2023. PMID: 37338275
Venetoclax-based therapy as a bridge to allogeneic hematopoietic cell transplantation in children with relapsed/refractory AML.
Pfeiffer T, Li Y, Ashcraft E, Karol SE, Rubnitz JE, Epperly R, Madden R, Mamcarz E, Obeng E, Qudeimat A, Sharma A, Srinivasan A, Suliman A, Talleur AC, Velasquez MP, Gottschalk S, Triplett BM, Naik S. Pfeiffer T, et al. Among authors: qudeimat a. Bone Marrow Transplant. 2023 Mar;58(3):328-331. doi: 10.1038/s41409-022-01877-2. Epub 2022 Nov 29. Bone Marrow Transplant. 2023. PMID: 36443431 No abstract available.
18 results